Anti-inflammatory tripeptide

KPV.

The C-terminal tripeptide of alpha-MSH (Lys-Pro-Val), studied in the preclinical literature for its anti-inflammatory and gut-mucosal activity. Supplied as a 10 mg vial, or as a pre-filled research pen in 10 mg, 20 mg and 30 mg.

Key Information

CompoundKPV (Lys-Pro-Val)
Research categoryRegenerative Research
Available sizesVial: 10 mg  ·  Pen: 10 mg, 20 mg, 30 mg
PricingVial £30  ·  Pen £60 / £85 / £110. Prices exclude postage.
FormatLyophilised powder in sealed vial
Purity>99% by HPLC (Janoshik Analytical, batch-verified)
Intended useIn-vitro laboratory research only. Not for human consumption.

Chemical & Reference Data

Reference data drawn from public databases (PubChem, UniProt) and peer-reviewed literature. For research and laboratory characterisation only.

Compound classTripeptide (alpha-MSH C-terminal fragment)
Molecular formulaC16H30N4O4
Molecular weight342.44 g/mol
CAS Registry Number67727-97-3
Amino acid sequenceLys-Pro-Val (KPV)
Receptor / mechanismAnti-inflammatory signalling; melanocortin-pathway derived. Refer to primary literature.
Reported half-lifeShort; small tripeptide rapidly cleared once reconstituted.
SolubilityLyophilised powder reconstitutes in bacteriostatic water for laboratory use.
Storage (lyophilised)Stable at 2–8 °C lyophilised for 18+ months.
Storage (reconstituted)Reconstituted: store at 2–8 °C, use within 14 days.
Clinical / regulatory statusResearch compound. Not an approved medicine in the UK.

Research Profile

  • C-terminal tripeptide of alpha-MSH
  • Studied in anti-inflammatory and gut-mucosal models
  • Single lyophilised vial or pre-filled research pen
  • Third-party HPLC verified
  • Research use only

KPV is the Lys-Pro-Val tripeptide that forms the C-terminal sequence of the melanocortin alpha-MSH. It is characterised in the preclinical literature (for example Dalmasso et al. 2008 and Kannengiesser et al. 2008) for anti-inflammatory activity in intestinal-epithelial and colitis research models, retaining part of alpha-MSH's activity in a much smaller, more stable fragment. Supplied for in-vitro research use only.

The above describes how this compound is characterised in the published peer-reviewed literature. It is not a claim about effects in humans.

Laboratory Handling

KPV is supplied as a lyophilised (freeze-dried) powder in a sealed glass vial. For laboratory reconstitution, add the desired volume of diluent (typically bacteriostatic water) slowly down the side wall of the vial. Swirl gently until fully dissolved - do not vortex or shake. Store reconstituted solutions at 2–8 °C and use within 4–6 weeks.

Use our Reconstitution Volume Calculator to compute the resulting mg/ml concentration.

Purity & Verification

Every batch of KPV we supply is independently HPLC-verified by Janoshik Analytical. Where a Janoshik report has been issued for the current batch it is supplied with the order and carries a unique verification key that can be authenticated against Janoshik's records. Reported purity is consistently above 99%.

Related Compounds

Researchers working with KPV often work alongside the following compounds in the preclinical literature: